Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Stock · NYSE · Health Care
$41.48as of 10/16/2026
Price chart
Active signals
Support level
$33.96
Industry
Biotechnology: Pharmaceutical Preparations
TEVA Signal Track Record
How signals performed across all stocks →What TEVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +4.8% | 69% | October 9, 2026 |
| Bollinger Band Breakout | 26 | +5.8% | 69% | October 9, 2026 |
| Bollinger Band Breakdown | 18 | +0.9% | 56% | July 22, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -0.6% | 47% | July 22, 2026 |
| Any 20-session window (baseline) | +2.6% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cyto…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 31,173
- Website
- www.tevapharm.com/
Fundamentals
- 1-day range
- $40.96$41.7
- Market cap
- $40.56B
- P/E (trailing)
- 68.57
- P/E (forward)
- 13.42
- EPS (trailing)
- $0.60
- Dividend yield
- —
- Beta
- 0.45
- Avg. volume
- 5.68M
- Ex-dividend date
- November 28, 2017
- Dividend pay date
- December 12, 2017
52-week range
$6,207$12,990
Next earnings: November 3, 2026 · EPS estimate $0.73confirmed
How Teva Pharmaceutical Industries Limited American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 3, 2026 · via SEC EDGAR / Finnhub
Gross Profit$8.94B(52%)
Operating Income$2.16B(12%)
Forecasts
12 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$55
+32.6%
Median
$47.5
+14.5%
Low
$42
+1.3%
Teva Pharmaceutical Industries Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$19.67▲ 1.13%Market cap $53.78BP/E —$4,102$6,183
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $19.67 | ▲ 1.13% | $4,102$6,183 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette SyndromeYahoo · 10/2/2026
- Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric PatientsYahoo · 10/2/2026
- Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13Fintel · 10/2/2026
- Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026Benzinga · 10/2/2026
- Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette SyndromeBenzinga · 10/2/2026
- This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga · 10/1/2026
- Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst callsYahoo · 10/1/2026
- Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin ExpansionYahoo · 10/1/2026
- Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and MoreYahoo · 10/1/2026
Insider Activity
Insider Actions →Acquired
72.6K
Disposed
441.8K
- Savage Brian · September 18, 2026 · Option Exercise4.5K @ $34.7
- Savage Brian · September 18, 2026 · Sale314 @ $38.7
- Savage Brian · September 18, 2026 · Sale2.5K @ $39.15
- Savage Brian · September 18, 2026 · Sale4.5K @ $38.69
- Roberto Mignone · September 18, 2026 · Sale367.6K @ $39.06
- Amir Weiss · August 21, 2026 · Option Exercise2.5K @ $19.61
- Amir Weiss · August 21, 2026 · Sale2.5K @ $37.63
- Amir Weiss · August 21, 2026 · Sale6.9K @ $37.61
- Ronit Satchi-Fainaro · August 21, 2026 · Sale415 @ $37.25
- Evan Lippman · August 17, 2026 · Sale18.6K @ $36.57
- Tal Zvi Zaks · August 5, 2026 · Sale17 @ $34.87
- Placid Jover · August 3, 2026 · Option Exercise12.8K
- Placid Jover · August 3, 2026 · Sale12.8K @ $34.88
- Eric A. Hughes · August 3, 2026 · Option Exercise52.7K
- Eric A. Hughes · August 3, 2026 · Sale25.6K @ $34.88
Institutional Ownership
March 31, 2026
- Total shares held
- 697.45M
- Total value held
- $17.62B
- Institutional holders
- 649
Top holders this quarter
- Unknown65.14M
- Unknown45.96M
- Unknown42.78M
- Unknown40.82M
- Unknown39.63M
- Unknown38.45M
- Unknown37.90M
- Unknown33.13M
- Unknown27.77M
- Unknown17.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.